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cost 0.2 % to 58.01 % of the average monthly salary of the patient. In 2014, the least 
affordable drugs for patients with COPD were drugs from the inhaled corticosteroids 
group: Flixotide nebules, Nebufluzone and Pulmicort, the cost of which varied from 
19.86% to 58.01%, which can be afforded only by patients with incomes above the 
average. The most affordable drug is a short-acting β 2-agonist– salbutamol (Ca.s. 0.43-
15.70%). ConClusions: Ukraine faces a rather difficult situation for patients with 
COPD. Drugs recommended by GOLD are presented insufficiently, and a large number 
of drugs available in the market are not readily available to patients.
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objeCtives: Asthma is a chronic inflammatory airway disease that causes a 
significant economic and humanistic burden. The objective of this study was to 
systematically review the evidence on cost and resource utilization in uncontrolled 
and persistent asthmatic patients in Canada. Methods: A literature search was 
performed using keywords such as “asthma”, “hospitalization”, “medical services”, 
and “cost”. The search was conducted in the MEDLINE, EMBASE and PubMed elec-
tronic databases from January 1st 2005 to May 28th, 2015. To be eligible, studies had 
to be Canadian, focus on uncontrolled or persistent asthma and include cost or 
resource utilization data. Results: The search retrieved 17,335 studies of which 
7 fulfilled the eligibility criteria. Among the 7 retrieved studies on uncontrolled or 
persistent asthma, 6 reported resource utilization data and 3 reported cost data. 
Among the resource utilization studies, 6 reported data on hospitalizations, 4 on 
emergency department (ED) visits and 3 on physician visits at a patient-level. The 
hospitalization rate ranged from 15% to 64.5% per patient per year and the mean 
hospitalization length of stay was 1.83 days. The rates for ED visits ranged from 
3.4% to 50.4% with 2 studies reporting rates over 20%. One study reported a mean 
physician-visit rate of 50% per patient per year while another study reported that 
64.3% of the patients had at least 4 physician-visits per year. In the cost studies, 
the total mean direct cost in adjusted 2015CDN$ per patient per year ranged 
from $413 to $1,764, carrying overall additional cost for uncontrolled asthma to 
nearly $189 million annually in Canada. ConClusions: This analysis indicates 
that uncontrolled and persistent asthma is associated with considerable cost and 
resource use, especially regarding hospitalizations, ED visits and physician visits 
at a patient-level, thus leading to an important economic burden at a population-
level in Canada.
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objeCtives: Greece has increasing prevalence of tobacco use and one of the 
highest consumption rates in Europe. Notwithstanding that tobacco tax is an 
important fiscal revenue, smoking represents a major public health threat causing 
premature mortality, morbidity, costs and foregone productivity which are a major 
source of fiscal loss. The objective of this study was to assess the net fiscal impact 
of hypothetic tax increases to inform public policy. Methods: Evidence for the 
prevalence of smoking and smoking-attributable mortality (SAM) in Greece was 
synthesized with economic data to assess the net fiscal impact of tobacco use. 
SAM was converted into productivity (earnings) loss and tax revenue (fiscal) loss. 
Mincer functions were used to project lifetime earnings and direct and indirect per 
person tax for smokers and ex-smokers. Average tobacco consumption was used to 
quantify the expected tax revenue from tobacco consumption tax and published 
price elasticities were employed to explore the impact of hypothetical tax and 
price increases. Results: The averted mortality, by a 10% increase in the price of 
tobacco products, is expected to avert productivity loss of € 4.4-6.9 million that cor-
responds to averted fiscal loss of € 1.5-2.5 million as measured by expected lifetime 
tax. Based on previous studies, healthcare cost savings were estimated by previous 
studies at € 24-€ 149 million. Higher price increases yielded higher epidemiological, 
societal and fiscal benefits. Tobacco consumption appears to be inelastic thus, tax 
revenue was not reduced in the absence of lower consumption. ConClusions: 
Smoking represents both a source of fiscal revenue and loss for central govern-
ment. Price increases, through tobacco tax, may be a fiscally meaningful pol-
icy for reducing the burden of smoking. Although there are likely to be upper 
limits to which further tax increases will not discourage tobacco consumption. 
Assessing the net fiscal impact may be a useful tool for tobacco-control policy 
evaluation.
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objeCtives: Exacerbations of COPD contribute to overall disease severity and can 
be an important driver of increased healthcare resource utilisation. This study 
aimed to estimate COPD exacerbation rates and assess primary and secondary care 
resource utilisation in England, using GOLD 2013 categories from A: low risk, less 
symptoms to D: high risk, more symptoms. Methods: Patients with a diagnosis 
of COPD aged ≥ 40 years before January 1, 2011, registered in the Clinical Practice 
Research Datalink linked to Hospital Episode Statistics with complete spirometric 
and modified Medical Research Council Dyspnoea Scale information and exacer-
bation history were included and further classified into GOLD risk groups. Patient 
characteristics were described at baseline. Study outcomes were exacerbations 
rates, and resource utilisation comprised of general practitioner (GP) visits and 
77% in 2003 to 72% in 2012, only generic increased from 7% to 9% and mixed from 
16% to 19%. In 2012 the proportion generic dispenses was highest for salbutamol with 
53% in children and 51% in adults. ConClusions: Generic dispensing is increasing, 
probably due to preferential policy of the Dutch healthcare insurances. Switching 
drugs may increase confusion and mistakes in inhalation technique, causing less 
effective treatment and lower adherence.
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objeCtives: COPD market is highly boosted by combinations caused by over-
treatment and misclassification of the patients. Physicians have high tendency 
to prescribe triple combinations for COPD patients without making classification 
for severity. The objective of this analysis is to develop a clinical guideline based 
budget impact model for COPD to inform reimbursement decision. Methods: 
A model was developed to estimate the four-year budget impact of gradually 
increasing compliance with clinical guideline based treatment in COPD patients 
who are currently under overtreatment. Only inhaler drug acquisition costs from 
payer perspective were considered for each treatment class defined in the guide-
line. Inputs for the model were derived from 2 studies to compare the inhaler 
consumption in practice and guideline recommendation by categories. Patient per-
centage and treatment class used in each category are obtained from ALPHABET 
study, projected to the currently treated COPD population in Turkey. Indacaterol, 
a LABA, was taken into account as a first step of complying with guideline-based 
treatment approach based on its superior outcomes in first line medication. The 
model did not account for patient co-payments, drug prices are assumed to be 
constant in 4 years. Results: For a COPD market with a treatment regimen 
gradually complying with GOLD guideline in 4 years, the model estimated 20%( 
mioTL -24.7) cost reduction in government budget. From first to fourth year, the 
impact is -13%(mioTL-5.8),-17%(mioTL-6.0),-22%(mioTL-6.3) and -26%(mioTL-6.6) 
respectively. ConClusions: The model budget impact of implementing clinical 
guidelines with evolving treatment regimen towards LABA and LAMA combina-
tions and its mono components may reduce the overuse of drugs and government 
spending on COPD treatments. Based on these assumptions, budget impact of 
future treatment that will help physicians to comply with treatment guidelines 
may change. Model can be adapted accordingly. Reimbursement bodies might be 
better off moving toward aligning reimbursement decisions with clinical guide-
lines in the future.
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objeCtives: 1) To study the clinical, radiological and epidemiological features of severe 
pneumonia in children in age group of 1 month to 5 years of age; 2) To correlate clinical 
findings with radiological and bacteriological examination; 3) To know the choice of 
antibiotic for severe pneumonia. Methods: This was a prospective clinical study of 
severe pneumonia conducted on 200 children who were admitted to pediatric wards 
from October 2010 to September 2012 at Gout General Hospital, Guntur. The epidemio-
logical factors affecting the same were also studied. Results: Age groups/Number of 
cases Percentage: 1m–6m/67 33.5; 7m–12m/52 26; 13m–60m/81 40.5. Table 1: Distribution 
of cases according to age Sex Number of cases Percentage Male 130 65 Females 70 35 
Table 2: Distribution of cases according to sex Symptoms Number Percentage Cough 
199 99. 5 Fever 184 92 Hurried breathing 200 100 Refusal of feeds 80 40 Wheeze 50 25 
Convulsions 15 7. 5 Cyanosis 8 4 Table 3: Showing various symptoms ConClusions: 
ARI, especially severe pneumonia is one of the major causes of morbidity and mortality 
in children. Bronchopneumonia is the predominant form of presentation in infants and 
preschool children. Among the risk factors studied, inappropriate immunization for 
age, anemia, PEM grade III and IV were significant risk factors in severe pneumonia. 
Symptoms and signs mentioned in the WHO ARI control programme were very sensi-
tive and can be applied to hospitalized children. Chest X-ray is a valuable aid in the 
diagnosis of pneumonia in children. Follow up chest roentgenogram is vital for evaluat-
ing the response to treatment in pneumonia. Crystalline Penicillin and amikacin are 
still the antibiotics of choice in pneumonia. Indiscriminate use of higher antibiotics in 
not justified, in view of emergence of drug resistant organisms.
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objeCtives: A lifelong nature of COPD therapy requires significant costs from the 
patient’s budget. GOLD develops recommendations for the treatment of COPD, which 
correspond to the modern level of medicine and ensure proper quality of patients’ 
lives. The aim of this work is to identify the availability of drugs recommended by 
GOLD for patients in Ukraine from the perspective of physical availability of the 
drug in a pharmacy and in terms of its affordability. Methods: To determine the 
affordability of drugs, the paying capacity adequacy rate (Ca.s.) for 2014 was calcu-
lated. Results: In the Ukrainian market, there are 18 out of 32 drugs recommended 
by GOLD for the treatment of stable COPD course. A group of long-acting anticholin-
ergics (2 out of 4 drugs) and combined drugs glucocorticosteroids + β 2-agonists in 
one inhaler (2 out of 4 drugs) is presented insufficiently, and long-acting combina-
tions of anticholinergic + β 2-agonists are not available in the market. According to 
capacity adequacy rate (Ca.s.), in 2014 a month of treatment with the studied drugs 
